About Research Business Development

Research Business Development (RBD), with its Office of Technology Licensing (OTL), is COH’s value creation unit to assure COH’s academic and commercial interests are maximized and protected

• We interface system-wide with Duarte (CA) Beckman Research Institute and Medical Center as well as faculty at all clinical sites in California, Arizona, Georgia and Illinois, and provide actionable input to maximize potential IP strategies
• Trusted confidants and advisors for PIs and staff, with years of experience within and outside of City of Hope
• We are boots on the ground with industry, dedicating time and resources to understanding current market trends and forces. We generate licenses, collaborations and sponsored research from COH innovation; we generate new leads for clinical trials and manufacturing
• We are at the forefront of turning innovation into value for COH

Integrated Drug Development Venture (IDDV): City of Hope's Internal Drug Development Arm

The mission of City of Hope’s Integrated Drug Development Venture is to take innovation created by our Principal Investigators and generate high value pharmaceutical assets through preclinical and further clinical development at City of Hope. 

Through this initiative we lay the foundation for novel innovative drugs that can help patients world-wide, and for generating significant and sustainable licensing revenues for City of Hope.

Integrated Drug Development Venture (IDDV)

Focus: Biotech-like preclinical and early clinical development of selected internally-generated projects in a rigorous milestone-driven process; guided by external advisors with VC, Pharma, Biotech and Academic backgrounds, complemented by internal R&D Leaders

• Aim: Generate more highly-valued assets for
  • Licensing to existing companies
    - Example: City of Hope proprietary COVID vaccine licensed to GeoVax
  • Spinout of biotech companies

Overall Objective: Generate sustainable revenues back to City of Hope based on internally-generated therapeutic, diagnostic and platform assets; enabling valuable assets to reach the market and benefit patients world-wide.

City of Hope's IDDV portfolio currently comprises over a dozen projects

• Most assets are currently at the Lead Identification or Lead Optimization phase
• Strong focus on solid and hematological cancers as well as diabetes, anti-infectives
• Modalities include:
  • 5 small molecules
  • 4 antibodies/bispecifics
  • 4 cell therapies
  • 2 vaccines
  • 1 nucleic acid product
• Multiple additional assets have already been out-licensed at pre-clinical and clinical stages of development, and we are interested in finding additional licensees